Last reviewed · How we verify
JS207 for Injection
At a glance
| Generic name | JS207 for Injection |
|---|---|
| Sponsor | Shanghai Junshi Bioscience Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (PHASE2)
- A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer (PHASE2)
- JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC (PHASE2)
- JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JS207 for Injection CI brief — competitive landscape report
- JS207 for Injection updates RSS · CI watch RSS
- Shanghai Junshi Bioscience Co., Ltd. portfolio CI